| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/01/2023 | 34% | Chardan Capital | → $8 | Reiterates | Buy → Buy |
| 06/26/2023 | 17.25% | Piper Sandler | $10 → $7 | Maintains | Overweight |
| 05/16/2023 | 34% | Chardan Capital | → $8 | Reiterates | Buy → Buy |
| 05/04/2023 | 42.38% | Cantor Fitzgerald | → $8.5 | Initiates Coverage On | → Buy |
| 05/03/2023 | 34% | Chardan Capital | $10 → $8 | Maintains | Buy |
| 03/31/2023 | 34% | TD Securities | $10 → $8 | Maintains | Outperform |
| 03/31/2023 | 34% | Baird | $7 → $8 | Maintains | Neutral |
| 02/28/2023 | 67.5% | Chardan Capital | → $10 | Reiterates | → Buy |
| 02/01/2023 | 17.25% | Citigroup | $7.5 → $7 | Maintains | Buy |
| 01/31/2023 | 67.5% | Chardan Capital | $13 → $10 | Maintains | Buy |
| 01/31/2023 | 17.25% | Baird | $8 → $7 | Maintains | Neutral |
| 01/25/2023 | -33% | Morgan Stanley | $7 → $4 | Downgrades | Equal-Weight → Underweight |
| 12/15/2022 | 25.63% | Citigroup | $8 → $7.5 | Maintains | Buy |
| 09/30/2022 | 17.25% | Morgan Stanley | $8 → $7 | Maintains | Equal-Weight |
| 09/15/2022 | 117.76% | Chardan Capital | $18 → $13 | Maintains | Buy |
| 09/15/2022 | 34% | Baird | $11 → $8 | Maintains | Neutral |
| 09/15/2022 | 67.5% | BMO Capital | $12 → $10 | Maintains | Outperform |
| 06/15/2022 | 67.5% | Cowen & Co. | $14 → $10 | Maintains | Outperform |
| 06/15/2022 | 84.25% | Baird | $9 → $11 | Maintains | Neutral |
| 06/03/2022 | 34% | Morgan Stanley | $10 → $8 | Maintains | Equal-Weight |
| 04/07/2022 | 67.5% | Citigroup | $11 → $10 | Maintains | Buy |
| 02/10/2022 | 67.5% | Morgan Stanley | → $10 | Downgrades | Overweight → Equal-Weight |
| 01/13/2022 | 201.51% | Chardan Capital | $17 → $18 | Maintains | Buy |
| 11/23/2021 | 184.76% | Chardan Capital | → $17 | Initiates Coverage On | → Buy |
| 09/22/2021 | 151.26% | UBS | → $15 | Initiates Coverage On | → Buy |
| 09/20/2021 | 134.51% | Wedbush | → $14 | Initiates Coverage On | → Outperform |
| 09/14/2021 | 151.26% | Morgan Stanley | → $15 | Initiates Coverage On | → Overweight |
| 09/10/2021 | 117.76% | BMO Capital | → $13 | Initiates Coverage On | → Outperform |
| 08/23/2021 | 84.25% | Baird | → $11 | Initiates Coverage On | → Neutral |
| 08/23/2021 | 151.26% | Cowen & Co. | → $15 | Initiates Coverage On | → Outperform |
What is the target price for Li-Cycle Holdings (LICY)?
The latest price target for Li-Cycle Holdings (NYSE: LICY) was reported by Chardan Capital on August 1, 2023. The analyst firm set a price target for $8.00 expecting LICY to rise to within 12 months (a possible 34.00% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Li-Cycle Holdings (LICY)?
The latest analyst rating for Li-Cycle Holdings (NYSE: LICY) was provided by Chardan Capital, and Li-Cycle Holdings reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Li-Cycle Holdings (LICY)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Li-Cycle Holdings, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Li-Cycle Holdings was filed on August 1, 2023 so you should expect the next rating to be made available sometime around August 1, 2024.
Is the Analyst Rating Li-Cycle Holdings (LICY) correct?
While ratings are subjective and will change, the latest Li-Cycle Holdings (LICY) rating was a reiterated with a price target of $0.00 to $8.00. The current price Li-Cycle Holdings (LICY) is trading at is $5.97, which is within the analyst's predicted range.